why choose us

First received: September 19, 2022

Clinical Trial: A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Castration-Resistant Prostatic Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Brief Summary: Study CP-MGC018-03 is an open-label, two-part, Phase 2 study.Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT).ARAT includes abiraterone, enzalutamide, or apalutamide.Participants may have received up to 1 prior docetaxel-containing regimen, but no other chemotherapy agents.This part of the study will assess the efficacy and tolerability of vobramitamab duocarmazine (MGC018) in…

Read more